Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia
Relapsed/refractory (rel/ref) acute myeloid leukemia (AML) has a very high mortality rate. At present, hematopoietic stem cell transplantation (HSCT) is the most effective treatment for rel/ref AML. The remission of the primary disease before HSCT is crucial for the transplantation to be effective....
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2023.1117988/full |
| _version_ | 1828013068880183296 |
|---|---|
| author | Wenxiu Lv Wenxiu Lv Tianping Chen Shen Wang Chun Li Bo Zhang Liang Wang Fang Xv Fang Cao Jing Wang Li Chen Chenglin Liao Na Li Hongjun Liu |
| author_facet | Wenxiu Lv Wenxiu Lv Tianping Chen Shen Wang Chun Li Bo Zhang Liang Wang Fang Xv Fang Cao Jing Wang Li Chen Chenglin Liao Na Li Hongjun Liu |
| author_sort | Wenxiu Lv |
| collection | DOAJ |
| description | Relapsed/refractory (rel/ref) acute myeloid leukemia (AML) has a very high mortality rate. At present, hematopoietic stem cell transplantation (HSCT) is the most effective treatment for rel/ref AML. The remission of the primary disease before HSCT is crucial for the transplantation to be effective. Therefore, it is critical to choose a suitable type of chemotherapy before HSCT. Here, we recorded the outcomes of high-throughput drug sensitivity screening (HDS) in children with rel/ref AML. Thirty-seven pediatric rel/ref AML patients who received HDS from September 2017 until July 2021 were analyzed retrospectively. Most of the patients (24 patients, 64.9%) had adverse cytogenetics. Two patients had rel/ref AML with central nervous system leukemia. The complete remission (CR) rate was 67.6%. Eight patients developed IV grade bone marrow suppression. Twenty-three patients (62.2%) underwent HSCT. The 3-year overall survival (OS) and EFS rates were 45.9% and 43.2%, respectively. Infection in the myelosuppression stage was the main cause of death. The outcome of HDS was superior to the commonly reported rates. These results suggest that HDS may be a novel treatment option for pediatric patients with rel/ref AML, and it is a promising transitional regimen prior to HSCT. |
| first_indexed | 2024-04-10T09:40:37Z |
| format | Article |
| id | doaj.art-337e80bcdb4843dc9e2ee761c745a61a |
| institution | Directory Open Access Journal |
| issn | 2296-2360 |
| language | English |
| last_indexed | 2024-04-10T09:40:37Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj.art-337e80bcdb4843dc9e2ee761c745a61a2023-02-17T09:15:25ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602023-02-011110.3389/fped.2023.11179881117988Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemiaWenxiu Lv0Wenxiu Lv1Tianping Chen2Shen Wang3Chun Li4Bo Zhang5Liang Wang6Fang Xv7Fang Cao8Jing Wang9Li Chen10Chenglin Liao11Na Li12Hongjun Liu13Department of Hematology and Oncology, Anhui Provincial Children's Hospital (Anhui Hospital, Pediatric Hospital of Fudan University), Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Hematology and Oncology, Anhui Provincial Children's Hospital (Anhui Hospital, Pediatric Hospital of Fudan University), Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Hematology and Oncology, Anhui Provincial Children's Hospital (Anhui Hospital, Pediatric Hospital of Fudan University), Hefei, Anhui, ChinaRelapsed/refractory (rel/ref) acute myeloid leukemia (AML) has a very high mortality rate. At present, hematopoietic stem cell transplantation (HSCT) is the most effective treatment for rel/ref AML. The remission of the primary disease before HSCT is crucial for the transplantation to be effective. Therefore, it is critical to choose a suitable type of chemotherapy before HSCT. Here, we recorded the outcomes of high-throughput drug sensitivity screening (HDS) in children with rel/ref AML. Thirty-seven pediatric rel/ref AML patients who received HDS from September 2017 until July 2021 were analyzed retrospectively. Most of the patients (24 patients, 64.9%) had adverse cytogenetics. Two patients had rel/ref AML with central nervous system leukemia. The complete remission (CR) rate was 67.6%. Eight patients developed IV grade bone marrow suppression. Twenty-three patients (62.2%) underwent HSCT. The 3-year overall survival (OS) and EFS rates were 45.9% and 43.2%, respectively. Infection in the myelosuppression stage was the main cause of death. The outcome of HDS was superior to the commonly reported rates. These results suggest that HDS may be a novel treatment option for pediatric patients with rel/ref AML, and it is a promising transitional regimen prior to HSCT.https://www.frontiersin.org/articles/10.3389/fped.2023.1117988/fullpediatrichigh-throughput drug sensitivity screeninghematopoietic stem cell transplantation (HCST)relapsed/refractoryacute myeloid leukemia |
| spellingShingle | Wenxiu Lv Wenxiu Lv Tianping Chen Shen Wang Chun Li Bo Zhang Liang Wang Fang Xv Fang Cao Jing Wang Li Chen Chenglin Liao Na Li Hongjun Liu Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia Frontiers in Pediatrics pediatric high-throughput drug sensitivity screening hematopoietic stem cell transplantation (HCST) relapsed/refractory acute myeloid leukemia |
| title | Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia |
| title_full | Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia |
| title_fullStr | Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia |
| title_full_unstemmed | Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia |
| title_short | Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia |
| title_sort | feasibility of high throughput drug sensitivity screening hds guided treatment for children with refractory or relapsed acute myeloid leukemia |
| topic | pediatric high-throughput drug sensitivity screening hematopoietic stem cell transplantation (HCST) relapsed/refractory acute myeloid leukemia |
| url | https://www.frontiersin.org/articles/10.3389/fped.2023.1117988/full |
| work_keys_str_mv | AT wenxiulv feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT wenxiulv feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT tianpingchen feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT shenwang feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT chunli feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT bozhang feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT liangwang feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT fangxv feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT fangcao feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT jingwang feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT lichen feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT chenglinliao feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT nali feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia AT hongjunliu feasibilityofhighthroughputdrugsensitivityscreeninghdsguidedtreatmentforchildrenwithrefractoryorrelapsedacutemyeloidleukemia |